🇺🇸 FDA
Pipeline program

Veligrotug (VRDN-001)

VRDN-001-301

Phase 3 small_molecule completed

Quick answer

Veligrotug (VRDN-001) for Thyroid Eye Disease is a Phase 3 program (small_molecule) at Viridian Therapeutics, Inc.\DE with 1 ClinicalTrials.gov record(s).

Program details

Company
Viridian Therapeutics, Inc.\DE
Indication
Thyroid Eye Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials